Unicycive Therapeutics (NASDAQ:UNCY) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Unicycive Therapeutics (NASDAQ:UNCY) from a sell rating to a hold rating in a research note published on Saturday.

Several other research firms also recently weighed in on UNCY. Weiss Ratings raised Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 9th. HC Wainwright decreased their target price on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Benchmark decreased their target price on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a research report on Wednesday, July 1st. Guggenheim reissued a “buy” rating and issued a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday. Finally, Zacks Research cut Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Five equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $18.25.

Unicycive Therapeutics Trading Up 2.0%

Shares of Unicycive Therapeutics stock opened at $5.51 on Friday. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $8.74. The stock has a market cap of $153.48 million, a PE ratio of -3.15 and a beta of 1.79. The company has a 50-day moving average of $5.94 and a two-hundred day moving average of $6.64.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.41. On average, sell-side analysts forecast that Unicycive Therapeutics will post -1.17 EPS for the current fiscal year.

Institutional Trading of Unicycive Therapeutics

Several institutional investors have recently made changes to their positions in UNCY. Lazard Asset Management LLC acquired a new stake in shares of Unicycive Therapeutics during the 2nd quarter worth $55,000. JPMorgan Chase & Co. raised its position in shares of Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Unicycive Therapeutics in the 1st quarter worth $161,000. Bank of America Corp DE boosted its holdings in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after acquiring an additional 29,378 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Unicycive Therapeutics in the fourth quarter valued at $226,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Noble Financial raised its FY2026 EPS forecast to a loss of $0.62 from a loss of $1.62 and improved its Q3 and Q4 2026 estimates. The firm still projects positive earnings in 2027, although its FY2027 forecast was reduced to $3.70 from $4.33.
• Positive Sentiment: HC Wainwright maintained its Buy rating and $15 price target, implying substantial upside from recent trading levels. The firm’s long-term projections still call for a transition to profitability beginning in 2028.
• Positive Sentiment: Recent quarterly results exceeded expectations: Unicycive reported a quarterly loss of $0.06 per share versus the consensus estimate for a $0.47 loss, providing a favorable near-term earnings surprise.
• Neutral Sentiment: Wall Street Zen raised Unicycive to a Hold rating, signaling a more cautious view rather than a clear bullish or bearish change. Unicycive Therapeutics Raised to Hold at Wall Street Zen
• Negative Sentiment: HC Wainwright lowered several earnings forecasts. Its estimates now call for losses of $0.40 and $0.42 per share in Q3 and Q4 2026, respectively, and a $1.05 loss for FY2027. These revisions suggest a slower path to profitability.
• Negative Sentiment: Long-term earnings expectations were cut sharply: HC Wainwright reduced its FY2028, FY2029 and FY2030 EPS forecasts to $1.98, $3.08 and $3.11, respectively, from $3.04, $4.57 and $5.42. The revisions raise concerns about the timing and scale of future commercial success.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.